JP7862297B2 - 癌の治療 - Google Patents

癌の治療

Info

Publication number
JP7862297B2
JP7862297B2 JP2022513249A JP2022513249A JP7862297B2 JP 7862297 B2 JP7862297 B2 JP 7862297B2 JP 2022513249 A JP2022513249 A JP 2022513249A JP 2022513249 A JP2022513249 A JP 2022513249A JP 7862297 B2 JP7862297 B2 JP 7862297B2
Authority
JP
Japan
Prior art keywords
compound
formula
cancer
tumor
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022513249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546807A5 (cg-RX-API-DMAC7.html
JP2022546807A (ja
Inventor
クリストフ ディメイソン,
クリストファー スミス,
フランセスカ メルクリ,
トビアス ボールド,
マイケル ベッテス,
Original Assignee
アクセリア オンコロジー ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019903263A external-priority patent/AU2019903263A0/en
Application filed by アクセリア オンコロジー ピーティーワイ リミテッド filed Critical アクセリア オンコロジー ピーティーワイ リミテッド
Publication of JP2022546807A publication Critical patent/JP2022546807A/ja
Publication of JP2022546807A5 publication Critical patent/JP2022546807A5/ja
Application granted granted Critical
Publication of JP7862297B2 publication Critical patent/JP7862297B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2022513249A 2019-09-04 2020-09-04 癌の治療 Active JP7862297B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2019903263 2019-09-04
AU2019903263A AU2019903263A0 (en) 2019-09-04 Cancer treatment
AU2019904863A AU2019904863A0 (en) 2019-12-20 Cancer treatment (2)
AU2019904863 2019-12-20
PCT/AU2020/050936 WO2021042174A1 (en) 2019-09-04 2020-09-04 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026078263A Division JP2026129928A (ja) 2019-09-04 2026-05-07 癌の治療

Publications (3)

Publication Number Publication Date
JP2022546807A JP2022546807A (ja) 2022-11-09
JP2022546807A5 JP2022546807A5 (cg-RX-API-DMAC7.html) 2023-09-11
JP7862297B2 true JP7862297B2 (ja) 2026-05-19

Family

ID=74851931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513249A Active JP7862297B2 (ja) 2019-09-04 2020-09-04 癌の治療

Country Status (5)

Country Link
US (1) US20220347146A1 (cg-RX-API-DMAC7.html)
EP (1) EP4025203A4 (cg-RX-API-DMAC7.html)
JP (1) JP7862297B2 (cg-RX-API-DMAC7.html)
AU (1) AU2020343725B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021042174A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
NZ783377A (en) 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008529978A (ja) 2005-02-08 2008-08-07 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ 免疫原性分子
JP2012526092A (ja) 2009-05-08 2012-10-25 サイオクサス セラピューティクス リミティド 多価アジュバントディスプレイ
JP2013537892A (ja) 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
JP2014528955A (ja) 2011-10-06 2014-10-30 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
WO2016037240A1 (en) 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent
WO2018176099A1 (en) 2017-03-31 2018-10-04 Ena Therapeutics Pty Ltd Treatment of respiratory infection with a tlr2 agonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
IL275360B2 (en) * 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
JP2022546806A (ja) * 2019-09-04 2022-11-09 アクセリア オンコロジー ピーティーワイ リミテッド 癌免疫療法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008529978A (ja) 2005-02-08 2008-08-07 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ 免疫原性分子
JP2012526092A (ja) 2009-05-08 2012-10-25 サイオクサス セラピューティクス リミティド 多価アジュバントディスプレイ
JP2013537892A (ja) 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
JP2014528955A (ja) 2011-10-06 2014-10-30 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
WO2016037240A1 (en) 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent
WO2018176099A1 (en) 2017-03-31 2018-10-04 Ena Therapeutics Pty Ltd Treatment of respiratory infection with a tlr2 agonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8+T cell responses,Biomaterials,2017年,vol.137,pp.61-72
Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines,J. Med. Chem.,2019年08月16日,63,pp.2282-2291,DOI: 10.1021/acs.jmedchem.9b01044

Also Published As

Publication number Publication date
EP4025203A1 (en) 2022-07-13
US20220347146A1 (en) 2022-11-03
EP4025203A4 (en) 2023-12-20
AU2020343725A1 (en) 2022-03-24
JP2022546807A (ja) 2022-11-09
AU2020343725B2 (en) 2026-07-16
WO2021042174A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
KR100248030B1 (ko) 시토킨 조절제 및 시토킨 농도 변화에 관련된 병변 및 질환에 있어서 그의 용도
US20240173309A1 (en) Lipidated peptide inhibitors of interleukin-23 receptor
JP4896728B2 (ja) ブラジキニンb1受容体の拮抗薬
US10413614B2 (en) Conjugates for protection from nephrotoxic active substances
CN121371186A (zh) 癌症免疫疗法
US20220347146A1 (en) Cancer treatment
JP2024036660A (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン10薬剤
JP2026082831A (ja) 修飾ペプチドおよび関連する使用方法
JP6913130B2 (ja) 抗炎症性トリペプチド
US20090264345A1 (en) Macrocyclic peptides and methods for making and using them
EP2010203A2 (en) Macrocyclic peptides and methods for making and using them
US20230372551A1 (en) Radiolabeled ligands for targeted pet/spect imaging and methods of their use
US20240252693A1 (en) Folate receptor-targeted radiotherapeutic agents and their use
US10189875B2 (en) Anti-cancer peptide and use thereof
MXPA04011502A (es) Compuestos capaces de bloquear la respueta a sustancias quimicas o estimulos termicos o mediadores de la inflamacion de los nociceptores, un metodo para su obtencion y composiciones que los contienen.
AU2017290096A1 (en) Novel cyclic peptides and uses thereof
KR102499473B1 (ko) 여성 성기능장애를 치료하기 위한 신규한 펩타이드군
US20250121078A1 (en) Peptide drug conjugates and their uses
WO2022246141A2 (en) Peptide drug conjugates specific to fibronectin isotypes for cancer therapy
BR112018001207B1 (pt) Uso de um peptídeo no tratamento ou na prevenção de câncer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260507

R150 Certificate of patent or registration of utility model

Ref document number: 7862297

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150